News | February 09, 2026
Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
